About Epigenomics AG

Company Description

We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high medical need. Using blood as a liquid biopsy can improve patient access to cancer screening and thereby contribute to eradicate today’s deadliest cancer types such as colorectal, liver, and lung cancer. By leveraging our product pipeline and strong intellectual property, we aim to become a global leader in blood-based cancer detection.

Year founded

1998

Served area

Worldwide

Headcount

32

Headquarters

Geneststraße 5, 10829 Berlin – Germany

Publications

Insider Trades

Date Trading entity / Person Association Trade type Volume Average price
27.12.22 Ho, Dr. Selwyn Board Buy 4,200.00 € 27.12.22
23.12.22 von Prondzynski, Heino Supervisory board Buy 5,625.00 € 23.12.22
22.12.22 Lubenow, Dr. Helge Supervisory board Buy 1,934.20 € 22.12.22
22.12.22 Ahlers, Felix Board Other 22,000.00 € 22.12.22
20.12.22 von Prondzynski, Heino Supervisory board Buy 3,680.00 € 20.12.22
16.12.22 Lindenice GmbH Board Buy 7,400.00 € 16.12.22
16.12.22 IDAB Management GmbH Supervisory board Buy 7,400.00 € 16.12.22
16.12.22 Ho, Dr. Selwyn Board Buy 6,780.00 € 16.12.22
14.12.22 von Prondzynski, Heino Supervisory board Buy 40,000.00 € 14.12.22

Shareholder information

Shares outstanding

16,357,301

IPO

July 19, 2004

Designated Sponsor(s)

Pareto Securities

Stock exchange(s)

Frankfurt Stock Exchange

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.